| Document Date: 2013-01-25 10:07:58
Open Document File Size: 2,37 MBShare Result on Facebook
City NLX / / Company Bayer/ Ortho-McNeil Pharmaceutical / Novartis / The Medicines Company / Ortho-McNeil Pharmaceutical / THOMSON REUTERS / Forest Laboratories / Thomson Pharma / J&J Pharmaceutical Research / Genentech / Targacept / J&J Pharmaceutical Research and Development / Wyeth / THOMSON SCIENTIFIC LIMITED / Developer MAP Pharmaceuticals / Johnson & Johnson / Bayer / ImClone Systems / Migraine MAP Pharmaceuticals / Dyax Corp / Infinity Pharmaceuticals / Pfizer / MedImmune / Cilag / Developer ImClone Systems / Schering-Plough / Ironwood Pharmaceuticals / AstraZeneca / / Continent America / Europe / Asia / / Country Switzerland / Netherlands / Japan / Canada / United Kingdom / Germany / Sweden / Belgium / United States / / Currency USD / pence / / / Event Earnings Announcement / FDA Phase / Earnings Guidance / Funding / / Facility National Institute of Mental Health / / IndustryTerm pharmaceutical industry / cancer therapy / treatment for Alzheimer’s disease / marketed product / treatment of constipation-predominant irritable bowel syndrome / migraine therapies / pharmaceutical sales / treatment of cancer / pharmaceutical advance / stroke prevention / consistent and convenient dosing / pharmaceutical competitive intelligence solution / drug delivery technology / treatment of Crohn’s disease / / MedicalCondition photophobia / cancer NovaRx / ovarian cancer / multiple myeloma / disseminated intravascular coagulation / venous blood clots / macular degeneration / HAE / melanoma / non-small-cell lung cancer / disorder / perioperative hypertension / illness / cardiovascular diseases / Breast cancer / gastrointestinal stromal tumor / pneumonia / cancer / III gastric cancer / NSCLC / diabetic foot infection / migraines / hepatocellular carcinoma / incurable disease / stroke / target tumor / therapies slow disease / chronic idiopathic constipation / diabetic foot infections / acute coronary syndrome / ulcerative colitis / vomiting / deep vein thrombosis / hospital-acquired infections / chronic migraine / Parkinson’s disease / diseases / allergic reactions / stable disease / atrial fibrillation / infection / constipation-predominant irritable bowel syndrome / depression / severe skin infections / metastatic melanoma / major depressive disorder / Late-stage non-small-cell lung cancer / solid tumors / nausea / colorectal cancers / metastatic breast cancer / intense abdominal pain / Hereditary angioedema / skin and soft tissue infections ( csssi ) / phonophobia / chronic wounds / pulmonary embolism / hypersensitivity / renal cell carcinoma / infections / cancers / Alzheimer’s disease / disease / gastrointestinal and pulmonary side effects / bowel syndrome / prostate and ovarian cancer / Crohn’s disease / migraine / certain tumor / liver cancers / pain / metastatic malignant melanoma / drug-induced angioedema and capillary leak syndrome / venous thromboembolism / II prostate cancer / Hereditary angioedema Jerini Bridion / / MedicalTreatment surgery / oral therapy / cancer therapy / hip surgery / relaxation / antibiotics / alternative therapy / chemotherapy / mechanical ventilation / gene therapy / knee replacement surgery / / Organization FDA / European Union / National Institute of Mental Health / US National Headache Foundation / / Product Lovenox / Gleevec / Avastin / Nexavar / Aricept / penicillin / Factor Xa / JSM-6427 / EU / HCC / Europe / Trials DRUG / Firazyr / MAP-0004 / Xarelto / HAE / MRSA antibiotic / perioperative / DISEASE COMPANY Zeftera™ Complicated / AG-011 / / Technology chemotherapy / treating cancer / Immunodrug™ technology / Tempo drug delivery technology / CAD / gene therapy / phage display / /
SocialTag |
THE ONES TO WATCH Image Copyright: THOMSON REUTERS A PHARMA MATTERS REPORT. JULY–SEPTEMBER 2008